Dr. Diane Yamada specializes in the diagnosis and treatment of gynecologic cancers. She is the Section Chief for Gynecologic Oncology at the University of Chicago.
Her areas of interest include:
Surgery for gynecologic malignancies including ovarian, uterine and cervical cancers, as well as minimally invasive surgery
Prophylactic surgery for women at high risk for the development of hereditary ovarian and endometrial cancers
Management of high grade uterine cancers
Intraperitoneal chemotherapy
Novel clinical trials
Her research focuses on new treatments and drug development for ovarian and endometrial cancer, the regulation and radiologic imaging of ovarian cancer metastasis and the unique biology of aggressive uterine cancers. She conducts clinical trials targeting ovarian cancer as well as endometrial cancer.
Dr. Yamada is an editorial reviewer for a number of academic medical journals, including the American Journal of Obstetrics and Gynecology, Gynecologic Oncology, and Cancer. She is also the author or co-author of numerous peer-reviewed publications, book chapters and reviews concerning gynecologic cancers. She holds national leadership positions on the gynecologic oncology board of the American Board of Obstetrics and Gynecology and she is President-Elect II for the Society of Gynecologic Oncology.
University of California Los Angeles
MD
Harbor-UCLA Medical Center
Internship
Harbor-UCLA Medical Center
Residency
University of California, Irvine
Fellowship
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. Gynecol Oncol. 2025 Mar; 194:18-24.
PMID: 39923680
Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors.
Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors. JCO Clin Cancer Inform. 2022 08; 6:e2200035.
PMID: 35985004
Jumping translocations of 1q in donor cell-derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature.
Jumping translocations of 1q in donor cell-derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature. Mol Clin Oncol. 2020 Apr; 12(4):365-373.
PMID: 32190321
Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome? Gynecol Oncol. 2019 07; 154(1):177-182.
PMID: 31056111
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.
PMID: 31043742
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16.
PMID: 30241606
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9.
PMID: 30174305
Second primary rhabdomyosarcoma of the uterine cervix presenting with synchronous ovarian Sertoli-Leydig cell tumor: An illustrative case of DICER1 syndrome.
Second primary rhabdomyosarcoma of the uterine cervix presenting with synchronous ovarian Sertoli-Leydig cell tumor: An illustrative case of DICER1 syndrome. Gynecol Oncol Rep. 2018 Aug; 25:94-97.
PMID: 30014022
Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens. Gynecol Oncol. 2018 06; 149(3):570-574.
PMID: 29656794
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301.
PMID: 29398710
President
Society of Gynecologic Oncology
2021 - 2022
Division Board, Gynecologic Oncology
American Board of Obstetrics and Gynecology
2014 - 2020